Lucid Diagnostics: Buy Rating Backed by Strong Growth, Financial Stability, and Strategic Expansion
I'm PortAI, I can summarize articles.
Analyst Anthony Vendetti from Maxim Group maintains a Buy rating on Lucid Diagnostics with a $3.00 price target, citing strong growth, financial stability, and strategic expansion. Lucid Diagnostics shows steady growth in testing volumes and is financially well-positioned, aiming to expand Medicare and private insurance coverage. Anticipated Medicare coverage approval by 2025 is a key catalyst. Canaccord Genuity also maintains a Buy rating with the same price target. LUCD's stock price increased by 0.91% over six months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments